Working… Menu
Trial record 85 of 535 for:    IFNA2 AND RBV AND HCV

Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00881582
Recruitment Status : Completed
First Posted : April 15, 2009
Last Update Posted : September 14, 2012
Riyadh Military Hospital
King Faisal Specialist Hospital & Research Center
Information provided by (Responsible Party):
Faisal M Sanai, King Abdulaziz Medical City

Brief Summary:

There is a distinct lack of published literature on the effect of combination treatment of PEG-interferon and ribavirin on post-renal transplantation hepatitis C virus (HCV) patients. Small case series have been published utilizing conventional interferon and/or ribavirin and the available data is extremely preliminary in nature. A small retrospective series of patients treated with Pegylated interferon and ribavirin published recently suggests that the treatment may be safe and efficacious. Unpublished reports from a few centers within Saudi Arabia also suggest a good safety profile and reasonable efficacy from this form of combination treatment.

The investigators aim to prospectively study the safety and efficacy of PEG-interferon and ribavirin combination therapy in post-renal transplant HCV-infected patients. Towards this 40 patients with histological evidence of liver disease will be recruited and the efficacy of the above medications studied.

The proposed study aims to evaluate the efficacy and safety of PEG-interferon and ribavirin combination therapy in the treatment of chronic HCV in renal transplant patients in a way that will allow management of such patients in an optimized manner.

Condition or disease Intervention/treatment Phase
Chronic Hepatitis C Renal Transplant Drug: Pegylated interferon alfa-2a plus ribavarin Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients
Study Start Date : January 2009
Actual Primary Completion Date : December 2011
Actual Study Completion Date : December 2011

Arm Intervention/treatment
Experimental: Pegylated interferon alfa-2a plus ribavarin
Pegylated interferon alfa-2a plus ribavarin for 48 weeks
Drug: Pegylated interferon alfa-2a plus ribavarin
PEG-interferon alfa-2a and ribavirin. Pegylated interferon alfa-2a - standard dose; plus ribavirin - standard dose (determined by creatinine clearance); for 24 to 48 weeks (genotypes 1 & 4: 48 weeks; genotypes 2 & 3: 24 weeks)
Other Names:
  • Pegasys®, F. Hoffman-LaRoche
  • Copegus®, F. Hoffman-LaRoche

Primary Outcome Measures :
  1. Sustained Virologic Response [ Time Frame: At 24 weeks post completion of treatment ]

Secondary Outcome Measures :
  1. Adverse event rate and number of cases of graft rejection [ Time Frame: Assessment at 4, 12, 24 and 48 weeks on treatment, and 24 weeks post completion of treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 68 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients, male and female, aged 18 - 68 years
  • Post renal transplant patients exceeding one year
  • Anti-HCV (Abbott HCV EIA 2.0, Abbott Diagnostic, Chicago, IL) positive > 6 months AND/OR
  • Detectable serum quantitative HCV-RNA (Cobas Amplicor HCV Monitor v2.0, Roche Molecular Systems, Pleasanton, CA) with lower limit of detection at 50 IU/mL
  • Compensated liver disease with the following minimum hematologic and biochemical criteria:
  • Hemoglobin > 10 g/dL
  • WBC > 3000/mm3 ; granulocyte count > 1,500/mm3
  • Platelet count > 75,000/mm3
  • Albumin within normal limits
  • TFT within normal limits
  • ANA < 1:320
  • Ultrasound of the liver obtained within the preceding 6 months of study entry
  • Liver biopsy prior to entry confirming a histological diagnosis consistent with HCV necroinflammatory score (METAVIR) > 1, and fibrosis score >/= 2.

Exclusion Criteria:

  • Previous treatment with interferon and / or Ribavirin - based therapy for chronic hepatitis C
  • Co-infection with HBV or HIV
  • Chronic alcohol abuse (daily consumption > 20 g/day)
  • Autoimmune or metabolic liver disease liver disease
  • Active drug-induced hepatitis or HAV
  • Decompensated liver disease (Child-Pugh classification B or C) including a past history of decompensation
  • Variceal bleeding
  • Evidence of severe retinopathy (e.g. CMV retinitis, macula degeneration) or clinically relevant ophthalmological disorder due to diabetes mellitis or hypertension
  • Neoplastic disease
  • Patients with a value of alpha-fetoprotein >100 ng/mL will be excluded from the study until imaging studies confirm the absence of HCC. Presence of HCC, as determined by other means will also exclude the patient from histological sampling.
  • Patients with documented or presumed coronary artery disease or cerebrovascular disease should not be enrolled if, in the judgment of the investigator, an acute decrease in hemoglobin by up to 4 g/dL (40 g/L) (as may be seen with ribavirin therapy) would not be well-tolerated
  • History of severe psychiatric disease, especially depression. Severe psychiatric disease is defined as treatment with an antidepressant medication or a major tranquilizer at therapeutic doses for major depression or psychosis, respectively, for at least 3 months at any previous time or any history of the following: a suicidal attempt, hospitalization for psychiatric disease, or a period of disability due to a psychiatric disease
  • Evidence of drug abuse (including excessive alcohol consumption) within one year of study entry
  • Current pregnancy, ongoing breast feeding or unwilling to have contraception
  • Bleeding or clotting diatheses
  • Recent history of renal allograft rejection (< 6 months)
  • Inability or unwillingness to provide informed consent or abide by the requirements of the study.
  • History or other evidence of severe illness or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study.
  • History of organ transplantation, other than kidney, with an existing functional graft.
  • Patients requiring dialysis or in whom dialysis is impending.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00881582

Layout table for location information
Saudi Arabia
King Faisal Specialist Hospital & Research Centre
Riyadh, Saudi Arabia, 11159
Riyadh Military Hospital
Riyadh, Saudi Arabia, 11159
Sponsors and Collaborators
King Abdulaziz Medical City
Riyadh Military Hospital
King Faisal Specialist Hospital & Research Center
Layout table for investigator information
Principal Investigator: Faisal M Sanai, MBBS, MD Riyadh Military Hospital

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Faisal M Sanai, Consultant Hepatologist & Liver Transplant Physician, King Abdulaziz Medical City Identifier: NCT00881582     History of Changes
Other Study ID Numbers: RMH-01-09
First Posted: April 15, 2009    Key Record Dates
Last Update Posted: September 14, 2012
Last Verified: September 2012
Keywords provided by Faisal M Sanai, King Abdulaziz Medical City:
Hepatitis c
Renal transplantation
Pegylated interferon
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis C
Hepatitis C, Chronic
Interferon alpha-2
Hepatitis A
Hepatitis, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Peginterferon alfa-2a
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Physiological Effects of Drugs